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Abstract: Restless legs syndrome (RLS) is a sleep-related movement disorder commonly 
involving an unpleasant urge to move the limbs, typically the legs. Dopaminergic agents rep-
resent the first-line therapy for RLS; however, long-term use of such drugs results in worsen-
ing symptoms due to “augmentation” or other adverse events. Gabapentin, an analog of the 
inhibitory neurotransmitter gamma-aminobutyric acid (GABA), is an anticonvulsant/analgesic 
agent. Gabapentin is only mildly effective in relieving RLS symptoms, perhaps a result of 
its poor absorption from the gastrointestinal (GI) tract. Gabapentin enacarbil is a prodrug of 
gabapentin specifically designed to enhance absorption via the GI tract, and hence provide 
improved circulating levels of gabapentin on metabolism. Clinical trials to date have demon-
strated favorable safety and (compared to traditional gabapentin) improved pharmacokinetics 
and efficacy in treating RLS symptoms. Thus, gabapentin enacarbil may prove to be a useful 
drug in treating RLS. An application of gabapentin enacarbil for treatment of RLS is currently 
pending with FDA for approval.
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Introduction
Restless legs syndrome (RLS) is a common, distressing disease that affects a significant 
percentage of the adult population. In the US, 2% to 3% of the population experience 
clinically bothersome symptoms severe enough to warrant treatment.1–3 RLS is char-
acterized by discomfort of the legs during rest or inactivity and involves an urge to 
move the legs to relieve the symptoms. It can occasionally also affect the arms. RLS 
symptoms are usually present or worsen in the evening.4 Because of the discomfort of 
the limbs during rest, RLS can reduce sleep quality, daily function, and overall quality 
of life. Several drugs are currently used to treat RLS: dopaminergic agents such as 
levodopa (in combination with carbidopa or benserazide), dopamine agonists (such as 
ropinirole, and pramipexole), and nondopaminergic medications such as gabapentin, 
clonazepam and oxycodone.5,6 Common side effects of these drugs are sedation, diz-
ziness, fatigue, nausea, and vomiting.
Gabapentin is an anticonvulsant drug and is approved in the United States for the 
treatment of postherpetic neuralgia7 and partial seizures.7–10 Gabapentin has also been 
shown effective in improving RLS symptoms, reducing the frequency of periodic leg 
movements and improving sleep quality, suggesting a potential role in treating RLS.11–15 
Gabapentin is not approved for the indication of RLS treatment, although it is often 
used off-label for this purpose.5,16,17 Additional placebo-controlled, double-blind clinical 
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as gabapentin enacarbil or XP1351228 (Figure 1). XP13512 
is being further developed by XenoPort Inc/Astellas Pharma/
GlaxoSmithKline. A New Drug Application (NDA) has been 
filed with the Food and Drug Administration (FDA) and the 
current Prescription Drug User Fee Act (PDUFA) goal date 
for its review is February 2010.
Drug design
Gabapentin enacarbil (XP13512) is a gabapentin prodrug. 
Specifically, it is an acyloxyalkylcarbamate analog with an 
efficient enzymatic conversion to gabapentin in tissues. In 
addition, gabapentin enacarabil is designed to be recognized 
as a substrate for two high-capacity nutrient transporters with 
broad distribution through the human intestinal tract. One 
of the two transporters, monocarboxylate transporter type I 
(MCT-1), regulates the absorption of small-chain fatty acids 
and may transport pharmaceutical agents across the intestine.31 
The second transporter is a sodium-dependent multivitamin 
transporter (SMVT). SMVT regulates absorption of the 
essential cofactors biotin, lipoate and pantothenate.32
Pharmacology
Gabapentin enacarbil is administered as an oral formulation. 
The pharmacology was evaluated as immediate-release (IR) 
and extended release (XR) formulations.33,34
Improved bioavailability
Gabapentin enacarbil is rapidly absorbed and undergoes 
efficient enzymatic hydrolysis to yield gabapentin in vivo. In 
contrast to gabapentin, which uses lower capacity transport 
receptors located only in the upper intestinal area, gabapentin 
enacarbil uses alternative, higher-capacity transport receptors 
found across the whole length of the gastrointestinal tract. 
Increased transport capacity allows the delivery of higher 
doses of gabapentin in good dose proportionality, avoiding 
uptake saturation at clinically relevant doses.
No saturation of transport was observed in a dose escala-
tion study up to 2800 mg using immediate release formula-
tion; the plasma concentration of gabapentin was observed to 
increase proportionally in accordance with an orally adminis-
tered dose of gabapentin enacarbil.33 In contrast, gabapentin 
transport was saturated at 1400 mg oral dose levels. In the 
same study, similar observations were made with extended 
release tablet formulations of gabapentin enacarbil, with no 
sign of transport saturation up to 2100 mg oral dose levels.
Improved oral bioavailability for gabapentin enacarbil 
compared to gabapentin has been demonstrated in animal 
and human pharmacokinetic studies. Cundy et al35 reported 
trials have also suggested potential uses of gabapentin in the 
treatment of painful neuropathies in patients with diabetes 
mellitus18 and anxiety disorders.19
However, gabapentin has inherent pharmacokinetic 
deficiencies that limit its clinical effectiveness: variable 
bioavailability and short half-life. In healthy volunteers as 
well as epilepsy patients, clinical pharmacokinetic stud-
ies demonstrate limited absorption and high inter-patient 
variability.20–23 Bioavailability of orally administered 
gabapentin is dose-dependent. Surprisingly, bioavailability 
actually decreases with increasing dosages. Specifically, the 
oral bioavailability of gabapentin is approximately 60%, 
47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, 
and 4800 mg/day given in 3 divided doses, respectively.24 
Importantly, the range of doses where bioavailability 
decreases coincides with doses reported to be useful to treat 
neuropathic pain.20
Saturation of the gabapentin transport pathway may 
account for the observed dose-dependent decrease in bio-
availability. Absorption of gabapentin is mediated by a 
low-capacity solute transporter, probably an L-type amino 
acid transporter, which is located mainly in the upper small 
intestine.25,26 It has been suggested that the high inter-patient 
variability due to non-responders in clinical trials18,27 could be 
because of lower abundance of transporters in these patients,28 
resulting in unpredictable plasma levels of gabapentin that 
may not reach therapeutically meaningful levels.
Gabapentin has a short half-life of just 5 to 7 hours. After 
oral administration and absorption, gabapentin is rapidly 
excreted via urine; therefore gabapentin must be dosed 3 to 
4 times a day to maintain therapeutic levels. The requirement 
of frequent administration can lead to noncompliance and 
missed doses which can reduce clinical effectiveness.29
Enhancing the effectiveness of gabapentin has long 
been a goal, and pregabalin was developed in this direction. 
Pregabalin is a structural analog of gabapentin, which does 
not bind to gamma-aminobutyric acid (GABA) receptors, 
and is approved as an add-on medication for epilepsy and 
neuropathic pain. In a small clinical trial, pregabalin was 
efficacious in treating primary RLS as well as secondary 
RLS, and further investigation with randomized, placebo-
controlled trials was recommended.30
In an attempt to address the pharmacokinetic limita-
tions of gabapentin, Cundy and coworkers at Xenoport Inc. 
designed and synthesized a series of analogs of gabapentin 
and selected one candidate for further development based on 
its physico-chemical properties, enzymatic stability, transport, 
and in vivo pharmacokinetics. This compound was designated Neuropsychiatric Disease and Treatment 2010:6 153
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Figure 1 Chemical structures of A) gabapentin and B) gabapentin enacarbil.
improved oral bioavailability, dose proportionality, and colonic 
absorption for the prodrug compared to gabapentin in rats and 
monkeys. Compared with intracolonic gabapentin, intracolonic 
gabapentin enacarbil exhibited a 17-fold and 34-fold higher 
exposure in rats and monkeys, respectively. In addition, in 
monkeys, gabapentin enacarbil capsules resulted in 84.2% 
oral bioavailability compared with 25.4% bioavailability after 
a similar oral gabapentin dose. Importantly, this improvement 
in bioavailability was also observed in a human study, specifi-
cally, it was reported that the oral bioavailability of gabapentin 
enacarbil compared to gabapentin was 74.5% vs 36.6%.33 
Based on the molecular weights and milligram-equivalent 
of gabapentin relative to the gabapentin enacarbil, a 365 mg 
dose of gabapentin as prodrug (700 mg) achieved higher or 
comparable plasma concentrations of gabapentin compared 
to a 1200 to 1400 mg dose of free gabapentin in immediate 
release formulation.33 Efficient oral absorption of gabapentin 
enacarbil and conversion to achieve higher and dose-dependent 
concentration of gabapentin in plasma will allow preparation 
of longer-acting extended release formulations.
Mode of action
After intestinal absorption, gabapentin enacarbil is rapidly 
converted to gabapentin and the latter is the active form. 
Although gabapentin is well established as an effective 
antiepileptic and antineuropathic pain drug, the underlying 
molecular mechanism of gabapentin is still not entirely 
clear.36 Gabapentin is a structural analog of GABA; however 
gabapentin does not interact significantly with any GABA 
subtype receptors,37,38 for instance, several studies reported no 
evidence that gabapentin binds substantially to any subtype 
of GABAB receptors.37,39,40 Even so, one study suggested 
that gabapentin acts as an agonist for a subset of GABAB 
receptors,41 which may negatively regulate voltage-gated Ca2+ 
channels42 and activate inwardly rectifying K+ channels.43 
Gabapentin has shown a direct effect on the excitability of 
sensory neurons by blockade of Ca2+ and Na+ channels or 
activation of K+ channels.44 Lee and coworkers demonstrated 
that gabapentin upregulated renal outer medullary potassium 
channel, thus reducing neuronal excitability, suggestive of an 
important role in gabapentin’s antiepileptic effect.45
D-serine, an agonist for N-methyl-D-aspartate (NMDA) 
receptors, reverses some of gabapentin’s actions.46 However, 
gabapentin does not directly interact with the glycine-NMDA 
complex,37,47 and a rat study concluded that D-serine and gab-
apentin do not act at the same site.48 Gabapentin also exhibits 
a profound synergistic anti-allodynic action with the AMPA 
receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione 
(CNQX).49 A recent study concluded that after peripheral 
nerve injury, gabapentin acts directly in the brainstem via 
a glutamate-dependent mechanism to stimulate descending 
inhibition to produce antihypersensitivity.50Neuropsychiatric Disease and Treatment 2010:6 154
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Suman-Chauhan and coworkers identified a high-affinity 
binding site for gabapentin in rat brain homogenate.38 Binding 
to this receptor was dependent on the system L transporter, 
indicating that gabapentin likely crosses the cell membrane and 
binding occurs intracellularly. There is no clear relationship 
between system L transporter binding and clinical efficacy of 
gabapentin.51 The binding site for gabapentin was subsequently 
identified as the α2δ subunit of voltage-gated Ca2+ channel 
using pig cerebral cortex membranes.52 Hendrich and cowork-
ers provided a definitive proof that gabapentin acts primarily 
at an intracellular location.53
Pharmacokinetics, safety  
and tolerability
Preclinical studies were conducted to establish the efficiency 
and conversion rate of gabapentin enacarbil to gabapentin in 
various tissues. Gabapentin enacarbil was chemically stable 
at physiological pH range as indicated by 95% recovery of 
the prodrug after incubation for 1 hour at 37°C in buffers over 
the pH range of 2 to 8.28 However, the prodrug was rapidly 
converted to gabapentin by non-specific esterases in intestinal 
and liver tissues from rats, dogs, monkeys, and humans. Rates 
of conversion to gabapentin in human intestinal and liver tis-
sue preparations at 1 mg protein/mL were 196 and 146 pmol/
min/mg protein. Similar rates of conversion were observed 
in rats and monkeys. After 1 hour of incubation at 37°C in 
tissue preparations of pancreatin, Caco-2 cells, rat plasma, 
human plasma, rat liver, and human liver, 52%, 18%, 47%, 
96%, 25%, and 4% of gabapentin enacarbil was recovered 
with release rates of gabapentin of 43%, 75%, 45%, 5%, 71%, 
and 81%, respectively.28 The conversion to gabapentin was 
quantitative in these studies and no formation of gabapentin 
lactam was observed. Both isomers of gabapentin enacarbil 
showed similar cleavage rates in human tissues. Gabapentin 
enacarbil also did not show substrate or inhibitor properties 
for major P450 isoforms in human liver homogenates.28 
Therefore, gabapentin enacarbil is likely to have significantly 
low drug–drug interaction following administration.
To understand the mechanism of transport, in vitro 
  transport studies across artificial lipid membranes were 
  carried out. Gabapentin enacarbil showed pH-dependent 
passive permeability across the membrane suggesting that 
the prodrug should have some ability to passively diffuse 
across cells.28 However, passive diffusion is likely a minor 
component because pKa of gabapentin enacarbil is 5.0. Using 
in vitro cell culture assays, the transport of gabapentin ena-
carbil was shown to be dependent on MCT-1 and SMVT.
To understand the biodistribution and oral bioavailability, 
pharmacokinetic studies were performed in rats and monkeys. 
A dose-proportional exposure to gabapentin was observed 
after oral administration of gabapentin enacarbil, while 
exposure to the intact prodrug was low. More than 95% of 
radio labeled [14C]-gabapentin enacarbil was excreted as 
gabapentin in urine in rats. In monkeys 84.2% of gabapentin 
enacarbil was excreted as gabapentin compared to 25.4% 
when gabapentin was delivered orally. Less than 1% of the 
intact prodrug was recovered in feces.53 In healthy human 
subjects, using supratherapeutic doses gabapentin enacarbil 
was converted rapidly to gabapentin after absorption. Blood 
levels of gabapentin were proportional to gabapentin enacar-
bil dose over the range of 2400 to 6000 mg (1250–3125 mg-
equivalent gabapentin). Blood concentrations of intact 
gabapentin enacarbil were low and transient (0.5% of 
the released gabapentin concentration at all doses).35 These 
studies indicate that gabapentin enacarbil is readily absorbed 
after oral delivery.
In addition to one molecule of gabapentin, hydrolysis 
of gabapentin enacarbil also produces one molecule each 
of carbon dioxide, acetaldehyde, and isobutyric acid. Both 
acetaldehyde and isobutyric acid are generally regarded as 
safe (GRAS) molecules by the FDA. Given that gabapentin 
enacarbil is converted into gabapentin, with a known safety 
profile, and also converted into GRAS compounds, it is 
likely that gabapentin enacarbil should exhibit a favorable 
safety profile. Consistent with this hypothesis, no signifi-
cant toxicities were observed with gabapentin enacarbil in 
monkeys following repeated oral administration of 2000 mg/
kg/day doses. In addition no detectable accumulation was 
observed after 2 weeks.35
In a randomized-sequence, double-blind, placebo-
controlled crossover study in healthy human subjects, gaba-
pentin enacarbil was well tolerated up to supratherapeutic 
doses.54 In this study 600 mg extended-release tablets of 
gabapentin enacarbil were administered as a single oral 
dose of 2400, 3600, 4800, or 6000 mg. In a 32 healthy vol-
unteer study, the most commonly reported adverse events 
were dizziness and nausea (50% and 25% of subjects, 
respectively). Two subjects experienced treatment-emer-
gent adverse events rated as severe: psychomotor retarda-
tion, vertigo, and sedation (4800 mg dose) and somnolence 
(6000 mg dose). All treatment-emergent adverse events 
were resolved without medical intervention. None of the 
adverse events led to study withdrawal. These data support 
that gabapentin enacarbil is safe and well tolerated with 
minimal side effects.Neuropsychiatric Disease and Treatment 2010:6 155
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To study the bioavailability of gabapentin enacarbil from 
immediate release formulation, pharmacokinetic studies were 
conducted in healthy volunteers in phase I clinical trials.34,55–57 
Single doses of IR gabapentin enacarbil (350, 700, 1400, 
2100, and 2800 mg orally; n = 40) or placebo (n = 10) were 
evaluated. After 1 week, approximately equimolar doses of 
gabapentin (200, 800, 1200, and 1400 mg) were given to 
participants. Gabapentin exposure with prodrug was dose-
proportional; bioavailability was 82.9% for the 350 mg dose 
and 79.7% for the 2800 mg dose. In contrast, with gabapentin 
parent the bioavailability was 65.2% and 26.5% with the 
lowest and the highest doses respectively. Multiple doses 
of gabapentin enacarbil (350, 400, 800, 1200 and 1400 mg 
orally; twice daily, n = 29), administered over 7 days, resulted 
in dose-proportional gabapentin. The bioavailability of gaba-
pentin ranged from 73.1% to 93.2%.
Bioavailability from sustained release formulation of 
gabapentin enacarbil (1200 mg orally) was evaluated either 
with (n = 10) or without food (n = 12). Gabapentin (600 mg 
orally; n = 11) taken without food served as a reference. 
Exposure to gabapentin from gabapentin enacarbil was 
higher in the with food group compared to the fasted group. 
Exposure to gabapentin was higher in prodrug groups than 
the gabapentin group. Bioavailability of gabapentin was 
46.5% and 73.7% for the fasted and fed gabapentin enacarbil 
groups respectively, while the bioavailability was 37.7% in 
parent drug group.58
The effect of fat content in food on gabapentin enacarbil 
absorption was evaluated under fasted, low-fat (200–300 kcal, 
6% from fat), moderate-fat (500–600 kcal, 30% from fat), 
and high-fat (1000 kcal, 50% from fat) conditions. The dif-
ferent fat contents did not appear to affect the absorption 
of the prodrug. The bioavailability of gabapentin was 42%, 
64%, 65%, and 76% in fasted, low-, medium-, and high-fat 
food conditions respectively.34
Potential for drug interactions between gabapentin 
  enacarbil, naproxen (an MCT-1 substrate) and cimetidine (an 
organic cation transporter 2 substrate) was evaluated to assess 
the alterations in drug absorption when the prodrug is used 
in combination with these and other transporter substrates. 
In healthy volunteers, gabapentin enacarbil did not affect the 
bioavailability of naproxen or cimetidine. The AUC values of 
gabapentin enacarbil, when co-administered in combination 
with naproxen or cimetidine, increased up to 12% and 24%, 
respectively. The results indicate that gabapentin enacarbil 
can be used together with MCT-1, organic cation transporter 
2, or other transporter substrates without the need to alter the 
dose regimes.59,60
Efficacy
Efficacy of gabapentin enacarbil was evaluated in several 
phase II and phase III trials. Because various phase I, II 
and III trials were recently summarized by Merlino et al 
2009,34 this review will focus on key phase II and III studies 
in conjunction with drug efficacy. Readers are encouraged 
to refer the review by Merlino et al for a summary of clinical 
trials prior to the publication of this article.
Efficacy of gabapentin enacarbil in relieving RLS symp-
toms was evaluated over a two week period in a multicenter, 
randomized, double-blind, placebo-controlled, crossover, 
polysomnographic phase IIa clinical trial in RLS patients. 
Patients were treated for two weeks with either gabapentin 
enacarbil (600 mg orally at 5 PM and 1200 mg orally 1 hour 
before bed) or placebo, with a 1-week washout period between 
treatments. At the end of the treatment period, a significant 
improvement was observed in RLS symptoms such as quality 
of sleep, number of awakenings per night and hours awake per 
night. Compared to 14.7% patients reporting improvement 
of RLS symptoms in placebo group, 79.5% of patients in the 
gabapentin enacarbil group reported either much improved 
or very much improved symptoms.61 Efficacy and tolerability 
of 1800 mg dose of gabapentin enacarbil was evaluated in 38 
naïve subjects with RLS, over 9 clinical sites.62 Patients were 
treated with 1800 mg/day for 14 days, with a 7-day washout 
period between treatment periods. After 14 days, significantly 
reduced RLS symptoms and improved sleep were observed 
in subjects with moderate-to-severe primary RLS while dose 
levels were well tolerated.
In a 12-week, multicenter, randomized, double-blind, pla-
cebo controlled phase III clinical trial, efficacy of gabapentin 
enacarbil (1200 mg/day orally at 5 PM) was evaluated in 
patients with primary RLS. Patients treated with gabapentin 
enacarbil showed an improved international RLS (IRLS) total 
score (–13.2) in contrast to placebo group (–8.8) at 2 weeks. 
On the investigator-rated CGI (Clinical Global Impression), 
significantly more gabapentin enacarbil-treated patients 
(76.1%) responded than placebo (38.9%). At the end of 
study more than 50% of gabapentin enacarbil-treated patients 
showed no sign of RLS over the 24-hour assessment period 
compared with 18% placebo patients.63,64
Long-term safety and efficacy of gabapentin enacarbil 
was evaluated in a second multicenter, placebo-controlled 
clinical trial involving 327 patients with primary moderate-
to-severe RLS symptoms.65 Patients received gabapentin 
enacarbil (1200 mg/day orally) at 5 PM for 24 weeks in 
a single-blind phase of trial. The initial 24 weeks phase 
was completed with 221 patients, out of which 194 (88%) Neuropsychiatric Disease and Treatment 2010:6 156
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responded either “much improved” or “very much improved” 
CGI scores. These patients were further entered into a   
12-week randomized, double-blind phase. Patients were given 
gabapentin enacarbil for either 12 weeks (1200 mg/day po) or 
for 2 weeks (600 mg/day po) and then placebo for 10 weeks. 
For the extended trial, the primary end-point was number of 
patients who relapsed or had worsening symptoms. Gabap-
entin enacarbil treated group showed a statistically significant 
lower proportion of relapses than placebo, 9% versus 23% 
respectively. A third phase III trial evaluated the safety and 
efficacy of 600 and 1200 mg/day over 12 weeks.66 Both 
dose groups of gabapentin enacarbil resulted in significantly 
improved IRLS and CGI scores than with placebo.
In addition to RLS, other indications are being investigated 
for gabapentin enacarbil.67 The additional indications include 
post-herpetic neuralgia, painful diabetic neuropathy, and 
migraine prophylaxis. Recently, top-line results were presented 
from a phase II clinical study of placebo, 1200, 2400 or 
3600 mg/day of gabapentin enacarbil dosed twice a day for 
treatment of post-herpetic neuralgia. All doses demonstrated 
statistically significant improvements over placebo on the 
change from baseline to the end of maintenance treatment in the   
24-hour average pain intensity score. This 14-week, double-
blind, placebo-controlled study enrolled 376 subjects experienc-
ing pain for at least 3 months following healing of herpes zoster 
skin rash. Gabapentin enacarbil was generally well tolerated at 
all doses, and the most common adverse events were dizziness 
and somnolence, and most were mild or moderate.
Conclusions
RLS is a sleep-related movement disorder which involves 
an undesirable sensation to move the legs, which improves 
with activity. It is typically worse in the evenings and nights. 
Dopaminergic agents are currently the most commonly 
prescribed therapy. Long-term use of dopaminergic drugs 
may cause augmentation or other side effects such as leg 
edema, dizziness, and nausea. Gabapentin, an analog of 
GABA, is an anticonvulsant/analgesic agent. Gabapentin is 
only mildly effective in relieving RLS symptoms, perhaps 
because of poor absorption from the gastrointestinal tract. 
Gabapentin enacarbil, a prodrug of gabapentin, is designed 
to enhance gastrointestinal absorption and hence enhance 
bioavailability of gabapentin. Clinical trials have shown 
gabapentin enacarbil to be a safe and effective drug for 
RLS. An application for approval of gabapentin enacarbil 
for treatment of RLS is currently pending with FDA for 
approval, and additional clinical indications are being 
pursued, including neuropathic pain. The addition of one 
more therapeutic option to the RLS drug armamentarium 
would provide more options to physicians dealing with RLS 
patients with refractory symptoms.
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